29 04 2016Enlarged Amryt Pharma joins Aim after reverse takeover of Fastnet
Orrick acted for Shore Capital, Stifel and The Davy Group, the investment banking syndicate advising on the reverse takeover of Amryt Pharmaceuticals by cash shell Fastnet Equity plc.
The transaction, financed by the issuance of shares, closed on April 19, 2016. As part of the transaction, Fastnet also raised ¬£10 million via a share placement and changed its name to Amryt Pharma plc.
Amryt is an orphan drug development company that also¬†owns German pharmaceutical company Birken AG (Birken) and Swiss biopharmaceutical company SomPharmaceuticals (Som). Birken has developed a recently approved drug for partial thickness wounds and a¬†promising potential orphan drug candidate to treat¬†epidermolysis bullosa, a rare genetic disease. The group is also developing promising drug candidates to treat acromegaly and Cushing‚Äôs disease.¬†
The Orrick team advising the investment banking syndicate was led by Hilary Winter (Picture) and included Katie Cotton, David Griffiths and Nell Scott (US Securities).¬†?
¬† Involved fees earner: Hilary Winter - Orrick; Katie Cotton - Orrick; David Griffiths - Orrick; Nell Scott - Orrick;
see all videos
Hong Kong has become a city of bright expansion, culture, and futuristic innovation. Fr
Fintech, it’s described as the disruption in financial services pushed by consume
On October 14th, 2016, the world’s leading corporate stars aligned for a momentou
More than 19 Excellences in the global economy at the VI Annual Edition of IAIR AWARDS&
It took place on 19 November 2015 at Palace Downtown in Dubai the 19th edition of the I